Quantum Biopharma (QNTM) Common Equity (2020 - 2026)

Quantum Biopharma has disclosed Common Equity across 7 years of filings, most recently posting -$1.4 million for Q1 2026.

• Common Equity for Q1 2026 came in at -$1.4 million, down 131.35% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.4 million (down 131.35% YoY), and the FY2025 annual result was $5.1 million, down 51.13% from the prior year.
• Common Equity came in at -$1.4 million for Q1 2026 at Quantum Biopharma, down from $5.1 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $148.9 million in Q3 2024 to a low of -$1.4 million in Q1 2026.
• The 5-year median for Common Equity is $8.9 million (2024), against an average of $23.1 million.
• Across the five-year window, Common Equity retreated 19.13% in 2024 and slumped 131.35% in 2026, its largest moves.
• Quantum Biopharma's Common Equity stood at $30.5 million in 2022, then slumped by 57.73% to $12.9 million in 2023, then declined by 19.13% to $10.4 million in 2024, then tumbled by 51.13% to $5.1 million in 2025, then tumbled by 127.83% to -$1.4 million in 2026.
• The last three Common Equity figures came in at -$1.4 million (Q1 2026), $5.1 million (Q4 2025), and $7.5 million (Q3 2025), per Business Quant data.